Quantitative Xylazine Measurement in ED
Launched by ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · Apr 22, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the presence of a substance called xylazine in patients who have experienced a non-fatal opioid overdose in the Emergency Department (ED). Xylazine is often found mixed with opioids, and this research aims to understand how common it is in these situations. The trial is looking to gather information from patients aged 18 and older who have had an opioid overdose and have blood and urine samples available for testing.
If you or a loved one has had an opioid overdose and are treated in the ED, you might be eligible to participate in this study. The trial will not include anyone under 18 years old. Participants can expect to provide waste blood and urine samples, which will be analyzed to help improve understanding of drug use patterns and potentially improve treatment options for individuals with substance use disorders. This research is important as it can provide valuable insights into the challenges faced by those struggling with opioid use.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ED patient
- • Opioid OD (both NPS and non-NPS)
- • Availability of waste blood specimens for analysis
- • Availability of waste urine specimens for analysis
- Exclusion Criteria:
- • - Children under 18
About Icahn School Of Medicine At Mount Sinai
The Icahn School of Medicine at Mount Sinai is a premier academic institution located in New York City, renowned for its commitment to advancing medical research, education, and patient care. As a leading sponsor of clinical trials, the institution leverages its state-of-the-art facilities and multidisciplinary expertise to drive innovative research initiatives aimed at improving health outcomes. With a focus on translational medicine, the Icahn School of Medicine collaborates with a diverse network of researchers, clinicians, and industry partners to explore novel therapies and interventions across a wide range of medical disciplines. Its rigorous scientific approach and dedication to ethical standards position it as a trusted leader in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Elmhurst, New York, United States
Patients applied
Trial Officials
Jennifer Love, MD, MS
Principal Investigator
Icahn School of Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported